Theravance Biopharma, Inc.: Madison Avenue Partners, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Madison Avenue Partners, LP amended its Schedule 13G stake filing for Theravance Biopharma, Inc., according to SEC accession 0001013594-26-001190. The filing updates the investor's previously reported beneficial ownership position in the biopharmaceutical company. Schedule 13G amendments are typically filed when a passive investor's stake crosses or adjusts past certain thresholds, though the headline did not disclose the specific percentage or share count. The change matters because it signals a shift in a significant institutional holder's position in Theravance. What to watch next is the full filing details, including the exact ownership percentage and any further 13G or 13D activity from Madison Avenue Partners.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Madison Avenue Partners, LP, Theravance Biopharma, Inc.